Today: 29 June 2026
Browse Category

NASDAQ:EWTX 18 December 2025 - 30 December 2025

Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next

Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next

NEW YORK — Friday, December 26, 2025. U.S. stocks are trading in a post-holiday session with major benchmarks close to flat, while biotech is notably weaker. Against that backdrop, Edgewise Therapeutics, Inc. is pulling back after a sharp midweek move tied to a clinical update in hypertrophic cardiomyopathy. As of the latest trade captured around 12:55 p.m. ET, EWTX traded near $26.00, down about 4.7% on the day, with an intraday range of $25.40 to $27.92 and volume above 1.0 million shares.
26 December 2025
·
Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

As of 8:54 a.m. ET in New York on Friday, December 26, 2025, U.S. stock exchanges have not yet opened for the regular session. Nasdaq Edgewise Therapeutics, Inc. is in focus heading into the post-holiday session after the company delivered an encouraging clinical update for EDG-7500—its investigational therapy for hypertrophic cardiomyopathy—that helped drive a sharp rally in the last session before Christmas. PR Newswire
26 December 2025
···
Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics, Inc. stock surged in intraday trading on Wednesday, December 24, 2025, after the company released a fresh update on EDG-7500, its investigational therapy for hypertrophic cardiomyopathy. By late morning, shares were trading around $26.37—up roughly 21% versus the prior close—after swinging between about $21.30 and $27.05 on the day, with volume above 2.2 million shares. The move follows a company announcement that it has completed Parts B and C of its Phase 2 CIRRUS-HCM trial and reported favorable interim safety observations from Part D—an update that several market outlets characterized as a meaningful de-risking moment for the program’s safety profile, especially around left ventricular ejection fraction and arrhythmia monitoring. PR Newswire+2Investing.com+2
24 December 2025
··
Edgewise Therapeutics (EWTX) Stock News Today: What’s Driving the Volatility, Analyst Forecasts, and Key Catalysts (Dec. 22, 2025)

Edgewise Therapeutics (EWTX) Stock News Today: What’s Driving the Volatility, Analyst Forecasts, and Key Catalysts (Dec. 22, 2025)

December 22, 2025 — Edgewise Therapeutics, Inc. is back in the spotlight as its stock price whipsaws following a sharp late-week surge and a fresh round of market commentary that mixes optimism about the company’s muscle-disease pipeline with familiar concerns about cash burn in a pre-revenue biotech. As of 18:40 UTC on Dec. 22, EWTX traded at $21.29, after swinging between $27.77 and $21.18 intraday, with volume running well above a million shares.
22 December 2025
··
Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next

Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next

Edgewise Therapeutics, Inc. is back in the spotlight heading into December 20, 2025—not because of a single blockbuster headline, but because the stock just posted a sharp, high-volume move that traders and long-term biotech investors both tend to notice. With Edgewise still a clinical-stage company, the share price often reflects a shifting mix of expectations for clinical readouts, perceived regulatory timelines, and sentiment in the biotech tape. In other words: EWTX can move fast—even when the company itself hasn’t issued fresh news in the last 24–48 hours.
21 December 2025
··
Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge

Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge

Edgewise Therapeutics, Inc. is ending mid-December 2025 in classic clinical-stage biotech fashion: big percentage swings, a sharp momentum breakout, and investors trying to decide whether the move is “new information” or simply “new positioning.” As of Saturday, December 20, 2025, EWTX is being widely quoted around $25.55—a level reached after a powerful jump in the prior U.S. session. StockAnalysis+1 What matters for readers tracking the stock isn’t just the price print. It’s the why: a late-stage neuromuscular story, a closely watched cardiovascular program, and a pipeline that can re-rate quickly on clinical updates—up or down. PR Newswire+1
20 December 2025
·
Edgewise Therapeutics (EWTX) Stock News and Forecast: Why Shares Rebounded on Dec. 19, 2025—and What Analysts Are Watching Next

Edgewise Therapeutics (EWTX) Stock News and Forecast: Why Shares Rebounded on Dec. 19, 2025—and What Analysts Are Watching Next

December 19, 2025 — Edgewise Therapeutics, Inc. is back in the spotlight after a sharp one-day rebound that followed a volatile stretch for the clinical-stage biotech. EWTX closed Dec. 19, 2025 at $23.01, up +8.79% on the day after trading between roughly $21.49 and $23.84 on elevated activity. Investing.com For investors, today’s price action is the “symptom.” The bigger story is the “disease biology”: Edgewise is building a pipeline aimed at muscular dystrophies and serious cardiac conditions, with multiple clinical readouts and program updates spaced across late 2025 and beyond. PR Newswire+1
19 December 2025
···
Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

December 18, 2025 — Edgewise Therapeutics, Inc. saw its shares slide sharply in Thursday trading, a reminder that clinical-stage biotech stocks can move fast even when there’s no single headline screaming for attention. EWTX finished the session around $20.35, down roughly 8.8% from the prior close, after trading between about $20.33 and $22.81. StockAnalysis That drop matters because the Edgewise story is still mostly about future clinical readouts and regulatory path clarity, not current product revenue. The company is advancing late-stage work in muscular dystrophies and also developing cardiac sarcomere modulators for conditions like hypertrophic cardiomyopathy and heart failure. PR Newswire+1
18 December 2025
··

Stock Market Today

  • Sugar Jumps as India Monsoon Falters; Brazil Output Squeezed
    June 29, 2026, 2:56 PM EDT. Sugar prices moved higher with July NY sugar up 2.58%, hitting a three-week top. August London white sugar added 2.13%, trading at a 9.5-month high. Traders pointed to weak monsoon rains in India, the No. 2 sugar producer, which got 42% less rain than normal and faces its softest monsoon in 11 years. Brazil's mills are expected to produce less sugar too, as more cane is shifted to ethanol, bringing the share down to 41.4% from 50.1% a year ago. Global supply fears built after trader Czarnikow moved its forecast from a surplus to a small deficit. A strong El Niño could further dent harvests in Brazil, India, and Thailand.
Go toTop